Alexander J. Dwyer

Email:Â dwyer171@umn.edu
Entering Class:Â 2016
Education:
University of Wisconsin, Madison
Biology-Neurobiology and Music Composition majors
B.S., 2016
University of Minnesota
Microbiology, Immunology and Cancer Biology Graduate Program
Ph.D., 2022
MSTP Student Governance:
- Student Advisory Committee, 2016-2017
Thesis Advisor: Brian Fife, Ph.D.
Publications (pubmed)
Dwyer AJ, Ritz JM, Mitchell JS, Martinov T, Alkhatib M, Silva N, Tucker CG, Fife BT. Enhanced CD4+ and CD8+ T cell infiltrate within convex hull defined pancreatic islet borders as autoimmune diabetes progresses. Sci Rep. 2021 Aug 25;11(1):17142. PMCID: PMC8387412
Tucker CG, Dwyer AJ, Fife BT, Martinov T. The Role of Programmed Death-1 in Type 1 Diabetes. Curr Diab Rep. 2021 May 6;21(6):20. PMCID: PMC8323125
Tucker CG, Mitchell JS, Martinov T, Burbach BJ, Beura LK, Wilson JC, Dwyer AJ, Singh LM, Mescher MF, Fife BT. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity. J Immunol. 2020 Sep 1;205(5):1449-1460. PMCID: PMC8293279
Dirice E, Kahraman S, De Jesus DF, El Ouaamari A, Basile G, Baker RL, Yigit B, Piehowski PD, Kim MJ, Dwyer AJ, Ng RWS, Schuster C, Vethe H, Martinov T, Ishikawa Y, Teo AKK, Smith RD, Hu J, Haskins K, Serwold T, Qian WJ, Fife BT, Kissler S, Kulkarni RN. Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes. Nat Metab. 2019 May;1(5):509-518. PMCID: PMC6696912
Martinov T, Swanson LA, Breed ER, Tucker CG, Dwyer AJ, Johnson JK, Mitchell JS, Sahli NL, Wilson JC, Singh LM, Hogquist KA, Spanier JA, Fife BT. Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. J Immunol. 2019 Aug 15;203(4):844-852. PMCID: PMC7083260
Work prior to the UMN MSTP:
McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015;11(10):2469-74. PMCID: PMC4635940